{
    "organizations": [],
    "uuid": "3ee21bd8c2e3354fe5e80b5382871524c6e22c96",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-redx-pharma-says-first-patient-dos/brief-redx-pharma-says-first-patient-dosed-in-phase-1-2a-trial-of-rxc004-idUSFWN1PV1GQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Redx Pharma Says First Patient Dosed In Phase 1/2a Trial Of RXC004",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 6 (Reuters) - Redx Pharma Plc:\n* ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2A CLINICAL TRIAL OF ITS ORAL PORCUPINE INHIBITOR RXC004 IN PATIENTS WITH HARD TO TREAT CANCERS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-02-06T15:39:00.000+02:00",
    "crawled": "2018-02-07T22:25:00.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "redx",
        "pharma",
        "plc",
        "announces",
        "first",
        "patient",
        "dosed",
        "phase",
        "clinical",
        "trial",
        "oral",
        "porcupine",
        "inhibitor",
        "rxc004",
        "patient",
        "hard",
        "treat",
        "cancer",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}